Favipiravir Adds Near-Equivalent Of AZ India To Glenmark's Sales
Antiviral favipiravir brings stunning gains to Glenmark, almost equal to the entire India sales of some multinationals, as demand surged amid the ferocious second of COVID-19 in the country. Such brand build-up could have taken five to seven years in pre-pandemic times, experts said.
You may also be interested in...
Fujifilm Toyama’s favipiravir may be relatively late on the Indian market,but local partner Dr Reddy’s believes that the large amount of safety data and superior shelf life of the product will hold it in good stead amid heightened competition. Local manufacturing could also help Dr Reddy’s pare the price differential with other versions.
Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.
Glenmark has received the go-ahead in India for its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process. While the firm says trial findings are in line with global data, with patients showing clinical improvements within the first seven days, social media is abuzz, with some physicians seeking greater clarity.